Filing Details
- Accession Number:
- 0001209191-20-050083
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-10 21:02:19
- Reporting Period:
- 2020-09-08
- Accepted Time:
- 2020-09-10 21:02:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1322505 | Albireo Pharma Inc. | ALBO | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1213040 | J. Martha Carter | C/O Albireo Pharma, Inc. 10 Post Office Square, Suite 1000 Boston MA 02109 | Chief Regulatory Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-09-08 | 10,000 | $19.19 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-09-08 | 10,000 | $45.55 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-09-09 | 7,500 | $19.19 | 7,500 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2020-09-09 | 2,500 | $24.04 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-09-09 | 7,500 | $38.68 | 2,500 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-09-09 | 2,500 | $39.82 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-09-10 | 9,312 | $24.04 | 9,312 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2020-09-10 | 688 | $24.48 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-09-10 | 10,000 | $42.41 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2020-09-08 | 10,000 | $0.00 | 10,000 | $19.19 |
Common Stock | Stock Option (right to buy) | Disposition | 2020-09-09 | 7,500 | $0.00 | 7,500 | $19.19 |
Common Stock | Stock Option (right to buy) | Disposition | 2020-09-09 | 2,500 | $0.00 | 2,500 | $24.04 |
Common Stock | Stock Option (right to buy) | Disposition | 2020-09-10 | 9,312 | $0.00 | 9,312 | $24.04 |
Common Stock | Stock Option (right to buy) | Disposition | 2020-09-10 | 688 | $0.00 | 688 | $24.48 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
10,000 | 2027-01-19 | No | 4 | M | Direct | |
2,500 | 2027-01-19 | No | 4 | M | Direct | |
29,000 | 2029-01-21 | No | 4 | M | Direct | |
19,688 | 2029-01-21 | No | 4 | M | Direct | |
12,312 | 2027-08-20 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.51 to $38.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $42.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- This option vests and become exercisable in equal installments on the last day of 16 consecutive calendar quarters beginning with March 31, 2017 and ending on December 31, 2020.
- This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023.
- This option vests and become exercisable in equal installments on the last day of 16 consecutive calendar quarters beginning with September 30, 2017 and ending on June 30, 2021.